Archives for News - Page 8
Tradjenta’s Carmelina cardiovascular outcome trial meets primary endpoint
Custom Synthesis, Boehringer Ingelheim and Eli Lilly released the positive top-line results from the trial, which evaluated the impact of treatment with Tradjenta compared with...
Better prevention can curbe significant disruption to daily life and work caused by migraine
Custom Synthesis, Novartis and the European Migraine and Headache Alliance (EMHA) Wednesday presented initial findings from the largest global migraine patient study to date, involving...
Sanofi and Advent in negotiations for €1.9 billion acquisition of Zentiva
Custom Synthesis, Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the companies have signed...
Novartis aims at spinoff of Alcon eye care devices business
Custom Synthesis, Novartis on Friday said it intends to spinoff Alcon, its eye care division, into a separately-traded standalone company, which would enable Novartis and...
CHMP recommends approval of Sanofi’s Cablivi
Custom Synthesis, The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment...
AstraZeneca’s lung cancer drug approved in Japan
Custom Synthesis, AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi...
Alvogen, Prestige BioPharma in Hervelous selling deal for Central and Eastern Europe
Custom Synthesis, Alvogen and Prestige BioPharma have entered into a deal for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar...
Myocant Sciences complets screening patients for heavy menstrual bleeding study
Custom Synthesis, Myovant Sciences has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating relugolix in...
NICE backs EUSA Pharma’s Qarziba for children
Custom Synthesis,The National Institute for Health and Care Excellence (NICE) has recommended the use of the EUSA Pharma’s targeted cancer immunotherapy, QARZIBA (dinutuximab beta)...
Wasdell Group launch serialisation service
Custom Synthesis, The Wasdell Group (Wasdell) has launched its serialisation service ahead of the EU FMD and US DSCSA implementation deadlines. Wasdell, an outsourcing partner...